FDA approves Artiva’s AlloNK and rituximab combo IND to treat SLE

17 Aug 2023
www.pharmaceutical-technology.com
Phase 1Drug ApprovalCell TherapyImmunotherapyGene Therapy
FDA approves Artiva’s AlloNK and rituximab combo IND to treat SLE
Preview
Source: Pharmaceutical Technology
AlloNK plus rituximab is intended to treat systemic lupus erythematosus in patients with active lupus nephritis. Credit: mi_viri / Shutterstock.com.
FDA approves Artiva’s AlloNK and rituximab combo IND to treat SLE
Preview
Source: Pharmaceutical Technology
The US Food and Drug Administration (FDA) has approved Artiva Biotherapeutics’ investigational new drug (IND) application for the combination of AlloNK (AB-101) and rituximab to treat systemic lupus erythematosus (SLE) in active lupus nephritis (LN) patients.
Designed to improve antibody-dependent cellular cytotoxicity (ADCC), AlloNK is a non-genetically modified, allogeneic, cord blood-derived, cryopreserved NK cell therapy candidate.
Recommended Reports
FDA approves Artiva’s AlloNK and rituximab combo IND to treat SLE
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - (Cannabidiol + Dronabinol) in Sedation GlobalData
FDA approves Artiva’s AlloNK and rituximab combo IND to treat SLE
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Siremadlin Succinate in Well Differentiated Liposarcoma GlobalData
View allCompanies IntelligenceArtiva Biotherapeutics IncView all
AlloNK is currently under assessment in two cancer trials, where it is being studied alongside antibody or NK-engager biologics.
In May 2022 the company revealed preliminary results from the dose-escalation stage of its Phase I/II clinical trial involving AB-101.
The trial, which focused on patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL), showed AlloNK’s therapeutic potential and favourable safety profile when used in conjunction with rituximab.
Artiva CEO Fred Aslan stated: “AlloNK given in combination with rituximab, an anti-CD20 antibody that targets B-cells, is already driving complete responses in late line B-NHL patients in an ongoing Phase I study by enhancing the activity of rituximab.
“Our hypothesis is that AlloNK plus rituximab also has the potential to drive deep B-cell depletion in LN patients with an off-the-shelf therapy that could be administered and managed in an outpatient setting.”
SLE is a severe autoimmune condition characterised by faulty B-cell activity and production of autoantibodies. Its clinical symptoms include end-organ damage and increased risk of death.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.By Cytiva Thematic
FDA approves Artiva’s AlloNK and rituximab combo IND to treat SLE
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.